202464-88-8 Usage
Description
(S)-Rasagiline Mesylate is a chemical compound that functions as a medication for the treatment of Parkinson's disease. It is characterized as a selective and irreversible inhibitor of monoamine oxidase-B (MAO-B), an enzyme responsible for the degradation of dopamine in the brain. The inhibition of MAO-B by (S)-Rasagiline Mesylate leads to an increase in dopamine levels, which is instrumental in alleviating motor symptoms associated with Parkinson's disease. This medication is commonly prescribed alongside other treatments for Parkinson's and is administered orally in tablet form, demonstrating efficacy in reducing motor symptoms and enhancing the overall functionality of patients with the condition.
Uses
Used in Pharmaceutical Industry:
(S)-Rasagiline Mesylate is used as a therapeutic agent for the treatment of Parkinson's disease, specifically targeting the motor symptoms associated with the condition. It is utilized for its ability to inhibit the activity of monoamine oxidase-B, thereby increasing dopamine levels in the brain and improving motor function in affected individuals.
Used in Combination Therapy for Parkinson's Disease:
(S)-Rasagiline Mesylate is used as an adjunctive medication in combination with other treatments for Parkinson's disease. This approach aims to provide a more comprehensive management of the condition, enhancing the overall therapeutic effect and potentially reducing the severity of motor symptoms experienced by patients.
Check Digit Verification of cas no
The CAS Registry Mumber 202464-88-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,0,2,4,6 and 4 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 202464-88:
(8*2)+(7*0)+(6*2)+(5*4)+(4*6)+(3*4)+(2*8)+(1*8)=108
108 % 10 = 8
So 202464-88-8 is a valid CAS Registry Number.
202464-88-8Relevant articles and documents
Pharmaceutical compositions comprising S-(?)-N-propargyl-1-aminoindan
-
, (2008/06/13)
Pharmaceutical compositions for the treatment of a neurological disorder of neurotrauma or for improving memory in a patient comprising a therapeutically effective amount of S-(?)-N-proparygl-1-aminoindan or a pharmaceutically acceptable salt thereof as active ingredient, and a pharmaceutically active carrier. The pharmaceutical compositions are adapted, in particular for treating a neurological hypoxia or anoxia, neurodegenerative diseases. Parkinson's Disease, Alzheimer's Disease, neurotoxic injury, head trauma injury, spinal trauma injury or any other form of nerve damage.
